HU181725B - Process for producing immunotherapeutic pharmaceutical composition - Google Patents
Process for producing immunotherapeutic pharmaceutical composition Download PDFInfo
- Publication number
- HU181725B HU181725B HU801726A HU172680A HU181725B HU 181725 B HU181725 B HU 181725B HU 801726 A HU801726 A HU 801726A HU 172680 A HU172680 A HU 172680A HU 181725 B HU181725 B HU 181725B
- Authority
- HU
- Hungary
- Prior art keywords
- nctc
- strains
- lysate
- cultured
- sodium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 230000001024 immunotherapeutic effect Effects 0.000 title description 2
- 239000006166 lysate Substances 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 239000007787 solid Substances 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims abstract description 4
- 241000588724 Escherichia coli Species 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004251 Ammonium lactate Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 229940059265 ammonium lactate Drugs 0.000 claims description 2
- 235000019286 ammonium lactate Nutrition 0.000 claims description 2
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- -1 sodium monohydrogen Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 208000019206 urinary tract infection Diseases 0.000 abstract description 2
- 206010022678 Intestinal infections Diseases 0.000 abstract 1
- 239000007640 basal medium Substances 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Die Erfindung betrifft ein Verfahren zur Herstellung eines immunobiotherapeutischen Praeparates fuer die Anwendung als Arzneimittel. Ziel der Erfindung ist die Bereitstellung eines solchen Praeparates zur Behandlung von Infektionen der Harnwege und des Darmtrakts. Erfindungsgemaess enthaelt das Praeparat als Wirkstoff ein Bakterienlysat aus mindestens einem der folgenden Escherichia coli-Staemme: NCTC-8603, NCTC-8621, NCTC-8623, NCTC-9026, NCTC-9111, NCTC-9119, NCTC-9707, NCTC-9708, I-081, I-082, I-083, I-084, I-085, I-086, I-087,I-088 undI-089.Es wird in der Weise hergestellt, dasz man jeden der angegebenen Staemme in einem festen oder fluessigen Grundmedium kultiviert, die Bakterien lysiert und/oder autolysiert und das Lysat isoliert. Erfindungsgemaesz kann auch das Lysat aller angegebenen Staemme isoliert und vermischt werden.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH692479A CH639852A5 (fr) | 1979-07-26 | 1979-07-26 | Medicament contre les maladies infectieuses des voies urinaires et digestives. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU181725B true HU181725B (en) | 1983-11-28 |
Family
ID=4317195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU801726A HU181725B (en) | 1979-07-26 | 1980-07-10 | Process for producing immunotherapeutic pharmaceutical composition |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS5622733A (de) |
| AR (1) | AR222887A1 (de) |
| BE (1) | BE884456A (de) |
| CH (1) | CH639852A5 (de) |
| CS (1) | CS212234B2 (de) |
| DD (1) | DD153192A5 (de) |
| DE (1) | DE3019448A1 (de) |
| ES (1) | ES491920A0 (de) |
| FR (1) | FR2462164A1 (de) |
| GB (1) | GB2054374B (de) |
| HU (1) | HU181725B (de) |
| IT (1) | IT1143025B (de) |
| PL (1) | PL127520B1 (de) |
| PT (1) | PT71612A (de) |
| RO (1) | RO80054A (de) |
| YU (1) | YU42532B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2550707B1 (fr) * | 1983-08-17 | 1986-02-28 | Lipha | Medicament immunomodulateur d'origine biologique et son procede de preparation |
| US4740585A (en) * | 1984-07-30 | 1988-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic vaccine against urinary infections |
| EP1641488B1 (de) | 2003-06-23 | 2011-03-30 | Biotech Tools S.A. | Epitop-zusammensetzung zur enterischen verabreichung hergestellt durch hydrolyse von antigenen strukturen mit chymotrypsin |
| CN101743019B (zh) * | 2007-03-05 | 2014-08-20 | Om药物公司 | 用于消化道或泌尿道病症的细菌提取物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1336015A (en) * | 1970-06-03 | 1973-11-07 | Unilever Ltd | Rearing pigs |
| US3911109A (en) * | 1971-10-14 | 1975-10-07 | Lever Brothers Ltd | Rearing calves |
| BE789864A (fr) * | 1971-10-14 | 1973-04-09 | Unilever Nv | Elevage des veaux |
| JPS5219927B2 (de) * | 1972-06-08 | 1977-05-31 | ||
| GB1462384A (en) * | 1973-04-12 | 1977-01-26 | Unilever Ltd | Rearing of lambs |
| US4141970A (en) * | 1975-05-07 | 1979-02-27 | Internationale Octrooimaatschappij "Octropa" B.V. | Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections |
| GB1560934A (en) * | 1975-05-07 | 1980-02-13 | Unilever Ltd | Methods for the resistance of non-human mammals to gastro-intestinal disorders |
| US4136167A (en) * | 1975-06-12 | 1979-01-23 | Internationale Octrooi Maatschappij "Octropa" B.V. | Process for reducing the incidence of neonatal diarrhoea in pigs |
| GB1581776A (en) * | 1976-08-18 | 1980-12-17 | Smith Kline Rit | Vaccines against oedema disease of piglets |
-
1979
- 1979-07-26 CH CH692479A patent/CH639852A5/fr not_active IP Right Cessation
-
1980
- 1980-05-21 DE DE19803019448 patent/DE3019448A1/de active Granted
- 1980-05-28 ES ES491920A patent/ES491920A0/es active Granted
- 1980-06-06 FR FR8012677A patent/FR2462164A1/fr active Granted
- 1980-07-10 HU HU801726A patent/HU181725B/hu unknown
- 1980-07-14 DD DD222593A patent/DD153192A5/de not_active IP Right Cessation
- 1980-07-22 RO RO80101780A patent/RO80054A/ro unknown
- 1980-07-24 BE BE0/201514A patent/BE884456A/fr not_active IP Right Cessation
- 1980-07-24 PL PL1980225853A patent/PL127520B1/pl unknown
- 1980-07-24 IT IT49314/80A patent/IT1143025B/it active
- 1980-07-25 YU YU1896/80A patent/YU42532B/xx unknown
- 1980-07-25 GB GB8024420A patent/GB2054374B/en not_active Expired
- 1980-07-25 PT PT71612A patent/PT71612A/pt unknown
- 1980-07-25 AR AR281940A patent/AR222887A1/es active
- 1980-07-25 CS CS805266A patent/CS212234B2/cs unknown
- 1980-07-25 JP JP10231580A patent/JPS5622733A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| YU189680A (en) | 1983-06-30 |
| ES8104402A1 (es) | 1981-04-01 |
| GB2054374A (en) | 1981-02-18 |
| JPH0255407B2 (de) | 1990-11-27 |
| DE3019448A1 (de) | 1981-02-12 |
| AR222887A1 (es) | 1981-06-30 |
| IT1143025B (it) | 1986-10-22 |
| FR2462164B1 (de) | 1983-08-05 |
| IT8049314A0 (it) | 1980-07-24 |
| GB2054374B (en) | 1983-06-22 |
| YU42532B (en) | 1988-10-31 |
| DE3019448C2 (de) | 1987-07-30 |
| PL127520B1 (en) | 1983-11-30 |
| ES491920A0 (es) | 1981-04-01 |
| DD153192A5 (de) | 1981-12-30 |
| PL225853A1 (de) | 1981-05-08 |
| RO80054A (ro) | 1982-10-26 |
| CS212234B2 (en) | 1982-03-26 |
| CH639852A5 (fr) | 1983-12-15 |
| JPS5622733A (en) | 1981-03-03 |
| PT71612A (fr) | 1980-08-01 |
| FR2462164A1 (fr) | 1981-02-13 |
| BE884456A (fr) | 1980-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1246445A (en) | Intestinal microflora-improving agent | |
| JP3653277B2 (ja) | ラクトバチルス菌株、該菌株の組成物および該菌株の使用法 | |
| DE69226622T2 (de) | Lyophilisierte Bakterien enthaltende Diät- oder Arzneimittelnzusammenstellungen | |
| CN117143783B (zh) | 一种唾液联合乳杆菌vb330及其应用 | |
| CH653556A5 (de) | Arzneimittel mit antitumor-wirkung. | |
| TWI754929B (zh) | 乳酸菌用於提升對腸病毒７１型之抵抗力之用途 | |
| CN117448198B (zh) | 一种动物双歧杆菌乳亚种vb301及其应用 | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| WO2019051790A1 (zh) | 单形巨单胞菌(Megamonas funiformis)及其应用 | |
| CN117106679A (zh) | 一种缓解胰岛素抵抗的益生菌剂及其应用 | |
| CN117159598A (zh) | 植物乳植杆菌Lp18在制备增强免疫的药物或保健食品方面的用途及产品 | |
| CN110062806B (zh) | 粪厌氧棒杆菌(Anaerostipes caccae)及其应用 | |
| GB2092890A (en) | Cyclodextrin compositions | |
| HU181725B (en) | Process for producing immunotherapeutic pharmaceutical composition | |
| KR0169982B1 (ko) | 피부염 치료용 약제 | |
| WO2019109348A1 (zh) | 丁酸杆菌(Butyribacter intestini)在预防和/或治疗炎症相关疾病的应用 | |
| JPS61271223A (ja) | 血中脂質改善剤 | |
| CN118530881A (zh) | 一种鼠李糖乳杆菌gg外泌体及其制备方法和应用 | |
| JP2969017B2 (ja) | 感染防御剤 | |
| EP0196858B1 (de) | Mittel zur Verbesserung der Lebensfunktion und Mittel zur Senkung des Blutdrucks | |
| CN114796289A (zh) | 一种抗腹泻中药微生态制剂及其制备方法和应用 | |
| WO2018107364A1 (zh) | 深圳柯林斯菌(Collinsella shenzhenensis)及其应用 | |
| JPS6069022A (ja) | 免疫調整剤及びその製造法 | |
| JP3273948B2 (ja) | 生理活性物質ｔｋｒ１７８５類、製造方法及び微生物 | |
| CN119679857B (zh) | 一种抑制魏氏梭菌的组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 |